Elanco Animal Health (NYSE:ELAN) Updates Q2 2024 Earnings Guidance

Elanco Animal Health (NYSE:ELAN) issued an update on its second quarter 2024 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 0.230-0.260 for the period, compared to the consensus earnings per share estimate of 0.240. The company issued revenue guidance of $1.1 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion. Elanco Animal Health also updated its FY 2024 guidance to 0.880-0.960 EPS.

Elanco Animal Health Stock Up 25.0 %

Shares of NYSE:ELAN traded up $3.38 during midday trading on Wednesday, reaching $16.90. The company’s stock had a trading volume of 10,798,967 shares, compared to its average volume of 4,450,793. The firm has a 50 day moving average of $14.96 and a 200-day moving average of $14.02. The firm has a market capitalization of $8.35 billion, a P/E ratio of -6.60, a PEG ratio of 1.42 and a beta of 1.34. The company has a quick ratio of 1.35, a current ratio of 2.75 and a debt-to-equity ratio of 0.92. Elanco Animal Health has a 12-month low of $7.88 and a 12-month high of $17.23.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Monday, February 26th. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.02). Elanco Animal Health had a negative net margin of 27.87% and a positive return on equity of 6.44%. The firm had revenue of $1.04 billion for the quarter, compared to analysts’ expectations of $1 billion. During the same period last year, the company posted $0.19 earnings per share. The business’s revenue for the quarter was up 5.1% compared to the same quarter last year. On average, research analysts anticipate that Elanco Animal Health will post 0.91 earnings per share for the current year.

Analyst Ratings Changes

Several analysts recently commented on ELAN shares. Morgan Stanley increased their price objective on shares of Elanco Animal Health from $16.00 to $17.00 and gave the company an overweight rating in a research report on Tuesday, February 27th. The Goldman Sachs Group raised their price target on shares of Elanco Animal Health from $12.50 to $14.00 and gave the company a sell rating in a report on Tuesday, February 27th. TheStreet raised shares of Elanco Animal Health from a d+ rating to a c- rating in a report on Friday, February 23rd. Finally, Barclays raised their price target on shares of Elanco Animal Health from $18.00 to $19.00 and gave the company an overweight rating in a report on Tuesday, February 27th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of Moderate Buy and an average price target of $16.71.

Insider Transactions at Elanco Animal Health

In other Elanco Animal Health news, Director R David Hoover acquired 20,000 shares of the stock in a transaction dated Wednesday, March 6th. The shares were purchased at an average price of $16.14 per share, for a total transaction of $322,800.00. Following the purchase, the director now directly owns 185,000 shares of the company’s stock, valued at $2,985,900. The acquisition was disclosed in a filing with the SEC, which is available at this link. Company insiders own 0.57% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.